Trials / Completed
CompletedNCT04096326
AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines
A Phase 2b Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of AGN-151586 in Participants With Moderate to Severe Glabellar Lines
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 198 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of AGN-151586 over a range of doses for the treatment of moderate to severe glabellar lines (GL).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AGN-151586 | AGN-151586 solution for injection. |
| DRUG | Placebo | Placebo solution for injection. |
Timeline
- Start date
- 2019-09-26
- Primary completion
- 2020-09-09
- Completion
- 2020-09-09
- First posted
- 2019-09-19
- Last updated
- 2023-07-28
- Results posted
- 2023-07-28
Locations
9 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04096326. Inclusion in this directory is not an endorsement.